{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T21:12:48Z","timestamp":1786396368181,"version":"build-2736575974"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,4,21]],"date-time":"2020-04-21T00:00:00Z","timestamp":1587427200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,4,21]],"date-time":"2020-04-21T00:00:00Z","timestamp":1587427200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100013583","name":"Afya Bora Consortium","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013583","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n<jats:title>Background<\/jats:title>\n<jats:p>Tuberculosis (TB) is the most common opportunistic infection and the leading cause of death in people living with HIV (PLHIV). HIV-infected children are at a higher risk of TB infection and disease compared to those without HIV. Isoniazid preventive therapy (IPT) is an effective intervention in preventing progression of latent TB infection to active TB. The World Health Organization (WHO) currently recommends that all children aged &gt;\u200912\u2009months and adults living with HIV in whom active TB has been excluded should receive a 6-months course of IPT as part of a comprehensive package of HIV care. Despite this recommendation, the uptake of IPT among PLHIV has been suboptimal globally. This study sought to determine the factors affecting IPT uptake and completion among HIV-infected children in a large HIV care centre in Nairobi, Kenya.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Method<\/jats:title>\n<jats:p>This was a cross-sectional mixed methods study comprising of quantitative and qualitative study designs. Medical records of 225 HIV-infected children aged 1 to &lt;\u200910\u2009years, in care in the Kenyatta National Hospital Comprehensive Care Centre (KNH CCC) were retrospectively reviewed, and 8 purposively selected healthcare providers and 18 consecutively selected caregivers of children were interviewed.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Results<\/jats:title>\n<jats:p>IPT uptake among CLHIV in care in the KNH CCC was 68% (152\/225) while the treatment completion rate was 82% (94\/115). IPT-related health education and counselling were the main facilitators of IPT uptake and completion, while fear of adverse drug reaction, pill burden and lack of an integrated monitoring and evaluation system for IPT were the major barriers.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Conclusion<\/jats:title>\n<jats:p>The IPT uptake in this study was low and fell short of the set global target of <jats:underline>&gt;<\/jats:underline>\u200990%. The completion rate was however acceptable. There is an urgent need to address the identified barriers.<\/jats:p>\n<\/jats:sec>","DOI":"10.1186\/s12879-020-05011-9","type":"journal-article","created":{"date-parts":[[2020,7,14]],"date-time":"2020-07-14T14:06:56Z","timestamp":1594735616000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":35,"title":["Factors affecting uptake and completion of isoniazid preventive therapy among HIV-infected children at a national referral hospital, Kenya: a mixed quantitative and qualitative study"],"prefix":"10.1186","volume":"20","author":[{"given":"Serah Kajuju","family":"Ngugi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Muiruri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theresa","family":"Odero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Onesmus","family":"Gachuno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,4,21]]},"reference":[{"key":"5011_CR1","unstructured":"UNICEF. Tuberculosis in children- UNICEF data (2019). Available at https:\/\/data.unicef.org\/topic\/child-health\/tuberculosis\/. Accessed 15 Jan 2020."},{"key":"5011_CR2","unstructured":"World Health Organization. Global tuberculosis report (2019). Available at https:\/\/www.who.int\/tb\/publications\/global_report\/en\/. Accessed 14 Jan 2020."},{"key":"5011_CR3","unstructured":"National Tuberculosis Leprosy and Lung Disease Program (NTLD-P). National guidelines on management of tuberculosis in children (2017). Available at https:\/\/www.chskenya.org\/wp-content\/uploads\/2018\/03\/National-Guidelines-on-Management-of-Tuberculosis-in-Children.pdf. Accessed 15 Jan 2020."},{"key":"5011_CR4","doi-asserted-by":"crossref","unstructured":"Venturini E, Turkova A, Chiappini E, et al. Tuberculosis and HIV co-infection in children. BMC Infect Dis. 2014;14(supp 1: S5).","DOI":"10.1186\/1471-2334-14-S1-S5"},{"key":"5011_CR5","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1186\/1741-7015-11-253","volume":"11","author":"SD Lawn","year":"2013","unstructured":"Lawn SD, Meintjes G, Mclleron H, et al. Management of HIV-associated tuberculosis in resource-limited settings: a state -of- the- art review. BMC Med. 2013;11:253.","journal-title":"BMC Med"},{"key":"5011_CR6","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1136\/thoraxjnl-2016-209421","volume":"72","author":"PJ Dodd","year":"2017","unstructured":"Dodd PJ, Prendergast AJ, Beecoft C, et al. The impact of HIV and ART on tuberculosis risk in children: a systematic review and meta-analysis. Thorax. 2017;72:559\u201375.","journal-title":"Thorax"},{"key":"5011_CR7","doi-asserted-by":"crossref","unstructured":"B-Lajoie M, Drouin I O, Bartlett G, et al. 1 Incidence and Prevalence of Opportunistic and Other Infections and the Impact of Antiretroviral Therapy Among HIV-infected Children in Low- and Middle-income Countries: A Systematic Review and Meta-analysis. Clin Infect Dis J 2016:62 (15 June) 1586\u20131594.","DOI":"10.1093\/cid\/ciw139"},{"issue":"1","key":"5011_CR8","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1056\/NEJMoa1011214","volume":"365","author":"SA Madhi","year":"2011","unstructured":"Madhi SA, Nachman S, Violari A, et al. Primary isoniazid prophylaxis against tuberculosis in HIV-exposed children. N Engl J Med. 2011;365(1):21\u201331.","journal-title":"N Engl J Med"},{"key":"5011_CR9","doi-asserted-by":"crossref","unstructured":"Suthar AB, Lawn SD, del Amo J, et al. Antiretroviral therapy for prevention of tuberculosis in adults with HIV: A systematic review and meta-analysis. PLoS Med. 2012;9(7).","DOI":"10.1371\/journal.pmed.1001270"},{"key":"5011_CR10","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1097\/01.aids.0000238406.93249.cd","volume":"20","author":"SD Lawn","year":"2006","unstructured":"Lawn SD, Myer L, Bekker LG, et al. Burden of tuberculosis in an antiretroviral treatment programme in sub Saharan Africa: impact on treatment outcomes and implications for tuberculosis control. AIDS. 2006;20:1605\u201312.","journal-title":"AIDS"},{"key":"5011_CR11","unstructured":"World Health Organization. Latent tuberculosis infection. An updated and consolidated guideline for programmatic management(2018). WHO, Geneva, Switzerland."},{"key":"5011_CR12","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1136\/thx.2010.156752","volume":"666","author":"LJ Frigati","year":"2011","unstructured":"Frigati LJ, Kranzer K, Cotton MF, Schaaf HS, Lombard CJ, Zar HJ, et al. The impact of isoniazid preventive therapy and antiretroviral therapy on tuberculosis in children infected with HIV in a high tuberculosis incidence setting. Thorax. 2011;666:496\u2013501.","journal-title":"Thorax"},{"key":"5011_CR13","doi-asserted-by":"crossref","unstructured":"Ayele HT, Mourik MS, Debray TP, Bonten MJ. Isoniazid prophylactic therapy for the prevention of tuberculosis in HIV infected adults: a systematic review and meta-analysis of randomized trials. PloS One. 2015;10(11).","DOI":"10.1371\/journal.pone.0142290"},{"key":"5011_CR14","unstructured":"Guidelines for tuberculosis preventive therapy among HIV- infected individuals in South Africa (2010). Available at https:\/\/www.who.int\/hiv\/pub\/guidelines\/south_africa_hiv_tb.pdf. Accessed 14 Jan 2020."},{"issue":"6","key":"5011_CR15","doi-asserted-by":"publisher","first-page":"596","DOI":"10.5588\/ijtld.17.0758","volume":"22","author":"I Pathmanathan","year":"2018","unstructured":"Pathmanathan I, Ahmedov S, Pevzner E, et al. TB Preventive Therapy for People Living with HIV \u2013 Key Considerations for Scale-Up in Resource-Limited Settings. Int J Tuberc Lung Dis. 2018;22(6):596\u2013605.","journal-title":"Int J Tuberc Lung Dis"},{"key":"5011_CR16","unstructured":"Policy statement on preventive therapy against tuberculosis in people living with HIV Report of a meeting held in Geneva 18-20 1998. World Health Organization\/UNAID. Available at http:\/\/whlibdoc.whoint\/hq\/19198\/WHO_TB_98.255.pdf."},{"key":"5011_CR17","unstructured":"World Health Organization: Guidelines for intensified tuberculosis case-finding and isoniazid preventive therapy for people living with HIV in resource constrained settings (2011). Available at http:\/\/whqlibdoc.who.int\/publications\/2011\/9789241500708_eng.pdf. Accessed 14 Jan 2020."},{"key":"5011_CR18","unstructured":"World Health Organization. Global tuberculosis report (2019). WHO, Geneva, Switzerland."},{"issue":"56","key":"5011_CR19","first-page":"3","volume":"29","author":"BW Taye","year":"2018","unstructured":"Taye BW, Kebede ZT. Isoniazid preventive therapy uptake and completion among HIV infected children in two referral hospitals, Northwest Ethiopia. Ethiop Med J. 2018;29(56):3.","journal-title":"Ethiop Med J"},{"issue":"2","key":"5011_CR20","doi-asserted-by":"publisher","first-page":"141","DOI":"10.24248\/eahrj.v3i2.611","volume":"3","author":"PM Mwangi","year":"2019","unstructured":"Mwangi PM, Wamalwa D, Marangu D, Obimbo EM, Ng\u2019ang\u2019a M. Implementation of isoniazid preventive therapy among HIV-infected children at health facilities in Nairobi County, Kenya: a cross-sectional study. East African Health Research Journal. 2019;3(2):141\u201350.","journal-title":"East African Health Research Journal"},{"key":"5011_CR21","volume-title":"Use of high burden country lists for TB by WHO in the post-2015 era","author":"World Health Organization","year":"2015","unstructured":"World Health Organization. Use of high burden country lists for TB by WHO in the post-2015 era. Geneva: World Health Organization; 2015."},{"key":"5011_CR22","unstructured":"National Tuberculosis Leprosy and Lung Disease Program (NTLD-P). Annual report 2017. Kenya. Available at https:\/\/www.nltp.co.ke\/annual-reports\/. Accessed 15 Jan 2020."},{"key":"5011_CR23","unstructured":"National Tuberculosis Leprosy and Lung Disease Program (NTLD-P). Annual report 2015. Kenya. Available at https:\/\/www.nltp.co.ke\/annual-reports\/#. Accessed 14 Jan 2020."},{"key":"5011_CR24","unstructured":"World Health Organization: Global tuberculosis report 2018. Geneva, Switzerland. Available at http:\/\/www.who.int\/tb\/publications\/global_report\/en\/. Accessed 3 Sep 2019."},{"key":"5011_CR25","unstructured":"National Tuberculosis Leprosy and Lung Disease Program (NTLD-P). Annual report 2016. Kenya. Available at https:\/\/www.nltp.co.ke\/annual-reports\/#. Accessed 15 Jan 2020."},{"key":"5011_CR26","unstructured":"CodePlex Archive. 2015. FGIQCare: IQCare Version 3.6. Available at https:\/\/fgiqcare.codeplex.com. Accessed 20 Nov 2018."},{"key":"5011_CR27","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1191\/1478088706qp063oa","volume":"3","author":"V Braun","year":"2006","unstructured":"Braun V, Clarke V. Using thematic analysis in psychology. Qual Res Psychol. 2006;3:77\u2013101.","journal-title":"Qual Res Psychol"},{"key":"5011_CR28","unstructured":"World Health Organization. The End TB strategy. Global strategy and target for tuberculosis prevention, care and control after 2015.  Available at https:\/\/www.who.int\/tb\/post2015_TBstrategy.pdf. Accessed 14 Jan 2020."},{"issue":"3","key":"5011_CR29","doi-asserted-by":"publisher","first-page":"204","DOI":"10.5588\/pha.13.0013","volume":"3","author":"EO Masini","year":"2013","unstructured":"Masini EO, Sitienei J, Weyeinga H. Outcomes of isoniazid prophylaxis among HIV-infected children attending routine HIV care in Kenya. Public Health Action. 2013;3(3):204\u20138.","journal-title":"Public Health Action"},{"key":"5011_CR30","doi-asserted-by":"publisher","first-page":"S49","DOI":"10.1097\/01.aids.0000391022.95412.a6","volume":"24","author":"B Durovni","year":"2010","unstructured":"Durovni B, Cavalcante SC, Saraceni V, Vellozo V, Israel G, et al. The implementation of isoniazid preventive therapy in HIV clinics: the experience from the TB\/HIV in Rio (THRio) study. AIDS (London, England). 2010;24:S49.","journal-title":"AIDS (London, England)"},{"key":"5011_CR31","doi-asserted-by":"crossref","unstructured":"Yirdaw K, Jerene D, Gashu Z, Edginton ME, Kumar AM, Letamo Y, Feleke B, Teklu AM, Zewdur S, Weiss B, Ruff A. Beneficial Effect of Isoniazid Preventive Therapy and Antiretroviral Therapy on the Incidence of Tuberculosis in People Living with HIV in Ethiopia. PLoS One. 2014;9(8).","DOI":"10.1371\/journal.pone.0104557"},{"key":"5011_CR32","first-page":"117","volume":"4","author":"MR DiMatteo","year":"1981","unstructured":"DiMatteo MR, Ron H. Social support and serious illness. Soc Netw Soc Support. 1981;4:117\u201348.","journal-title":"Soc Netw Soc Support"},{"key":"5011_CR33","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1097\/00002030-199701000-00016","volume":"11","author":"J Ngamvithayapong","year":"1997","unstructured":"Ngamvithayapong J, Uthaivoravit W, Yanai H, Akarasewi P, Sawanpanyalert P. Adherence to tuberculosis preventive therapy among HIV-infected persons in Chiang Rai, Thailand. Aids. 1997;11:107\u201312.","journal-title":"Aids"},{"issue":"SUPPL 5","key":"5011_CR34","first-page":"S27","volume":"24","author":"H Gatahun","year":"2010","unstructured":"Gatahun H, Granich R, Sculier D, et al. Implementation of isoniazid preventive therapy for people living with HIV worldwide: Barriers and solutions. AIDS. 2010;24(SUPPL 5):S27\u2013265.","journal-title":"AIDS"},{"key":"5011_CR35","doi-asserted-by":"publisher","first-page":"e18435","DOI":"10.1371\/journal.pone.0018435","volume":"6","author":"DA Gust","year":"2011","unstructured":"Gust DA, Mosimaneotsile B, Mathebula U, Chingapane B, Gaul Z, et al. Risk factors for non-adherence and loss to follow-up in a three-year clinical trial in Botswana. PLoS One. 2011;6:e18435.","journal-title":"PLoS One"},{"key":"5011_CR36","doi-asserted-by":"publisher","unstructured":"Harries AD, Lawn SD, Suthar AB, Granich R. Lancet Infect Dis 2015 Published Online October 27, 2015 https:\/\/doi.org\/10.1016\/S1473-3099(15)00242-X.","DOI":"10.1016\/S1473-3099(15)00242-X"},{"key":"5011_CR37","doi-asserted-by":"publisher","first-page":"723","DOI":"10.15585\/mmwr.mm6725a5","volume":"67","author":"AS Borisov","year":"2018","unstructured":"Borisov AS, Bamrah Morris S, Njie GJ, et al. Update of recommendations for use of once-weekly isoniazid-Rifapentine regimen to treat latent mycobacterium tuberculosis infection. MMWR Morb Mortal Wkly Rep. 2018;67:723\u20136.","journal-title":"MMWR Morb Mortal Wkly Rep"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-020-05011-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-020-05011-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-020-05011-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,20]],"date-time":"2021-04-20T23:56:17Z","timestamp":1618962977000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-020-05011-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,21]]},"references-count":37,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["5011"],"URL":"https:\/\/doi.org\/10.1186\/s12879-020-05011-9","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,21]]},"assertion":[{"value":"14 November 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 April 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 April 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Approval to conduct the study was obtained from Kenyatta National Hospital\/ University of Nairobi Ethics and Review Committee (Approval no. P709\/12\/2017) and the Kenyatta National hospital administration. Written informed consent was obtained from the participants before the interviews. The participants\u2019 information and consent forms were available in both the English and Swahili language versions with the participants choosing whichever language they were most comfortable with. For the quantitative component of the study which retrospectively reviewed medical records of children aged 1 to <\u200910\u2009years, no written consent was obtained from the parents or guardians. However, all personally identifiable information was removed from the dataset for privacy protection.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The quantitative component of the study involved retrospective review of medical records and data anonymised. The qualitative component had no identifying information for the participants. Hence, consent to publish the study findings was not possible or necessary.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"294"}}